Chugai Pharmaceutical Co., Ltd.
↗Tokyo, Japan
Chugai Pharmaceutical is a leading Japanese research-based pharmaceutical company and a member of the Roche Group. It specializes in the development of innovative drugs, particularly in the fields of oncology, immunology, and hematology. Chugai is known for its proprietary antibody engineering technologies and its strategic alliance with Roche, which holds a majority stake in the company.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Oncology and Immunology Therapeutics
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$8B-$9B
Founded:1925
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
Investors:Roche (Hoffmann-La Roche), The Master Trust Bank of Japan, Custody Bank of Japan
STOCK
Exchange:TYO
Ticker:4519
Market Cap:$65B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb, Bispecific antibody, Gene therapy, Cyclic peptide
Active Trials:45
Trial Phases:Phase 1: 12 | Phase 2: 18 | Phase 3: 15 | Phase 4: 5
FDA Approvals:15
EMA Approvals:12
CORPORATE STRUCTURE
Parent Company:Roche
Acquired By:Roche (Majority Owner) (2002-10-01)
Subsidiaries:Chugai Pharmabody Research (Singapore), Chugai Pharma USA, Chugai Pharma Europe
Key Partnerships:Roche (Strategic alliance for global commercialization), Eli Lilly (Out-licensing of orforglipron), Sarepta Therapeutics (Co-development of Elevidys)
COMPETITION
Position:Leader
Competitors:Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Eisai
LEADERSHIP
Key Executives:
Osamu Okuda - President & CEO
Iwaaki Taniguchi - CFO
Scientific Founders:Juzo Ueno
Board Members:Osamu Okuda, Iwaaki Taniguchi, Thomas Schinecker (Roche CEO), Boris L. Zaïtra
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Chugai Pharmaceutical Co., Ltd.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.